Content to Appear in Various Targeted Therapies and Oncology Publications and Websites
PLAINSBORO, N.J. (PRWEB) May 10, 2016
Targeted Healthcare Communications, the nation’s leading digital and print media enterprise focused on targeted cancer therapies, has entered into a collaborative agreement with the Society for Immunotherapy of Cancer (SITC) that centers on driving awareness and providing engaging content focused on cancer immunotherapy.
Under terms of the agreement, the new partnership will provide Targeted Therapies in Oncology, Targeted Oncology, Oncology Nursing News and OncLive readers and website visitors with unique and interesting cancer immunotherapy content. Specifically, the collaboration will highlight the importance of this new treatment option through articles on clinical topics, video interviews of faculty and researchers, a Targeted Therapies in Oncology column on immunotherapy and much more.
SITC is the world’s leading member-driven organization specifically dedicated to professionals working in the field of tumor immunology and cancer immunotherapy. It has long been regarded as the premier organization for scientific exchange, education and networking in the cancer immunotherapy field. The society is unique in that it serves as a catalyst for advancing cancer immunotherapy by bridging the gap between translational research, development and clinical practice. SITC brings together all aspects of the cancer immunology and immunotherapy community through its emphasis on high-caliber scientific meetings, dedication to education and outreach activities, focus on initiatives of major importance in the field, and a commitment to collaborations with like-minded domestic and international organizations, government and regulatory agencies, associations, and patient advocacy groups.
“SITC is comprised of cancer immunotherapy thought leaders and innovators, including academicians, government officials, regulators, industry professionals, practitioners and clinical and basic scientists, from around the world,” said Dr. Howard Kaufman, president of SITC and editor-in-chief of Targeted Therapies in Oncology and the Journal of Targeted Therapies in Cancer. “The combined experience and in-depth knowledge of our members will provide Targeted Healthcare Communications physician-based audiences with broad and engaging content on the importance of immunotherapy, as it becomes increasingly evident that we’re on the cusp of defining a new standard of care for patients with cancer.”
About Society for Immunotherapy of Cancer
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. Among its esteemed members, SITC counts influential basic and translational scientists, practitioners, healthcare professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere.
About Targeted Healthcare Communications
As cancer treatment has evolved dramatically over the past 10 years, with advances born of significant progress in the understanding of tumor development, genetics and pathology, the discovery of new pathways has transformed cancer treatment from chemotherapy regimens to advanced, sometimes complicated, targeted treatment options. Targeted Healthcare Communications leverages the growing interest in cancer products in precision medicine and is the first publisher with a peer-reviewed journal focusing on these new products. Through digital and print media platforms, the organization offers a dedicated website, two journals and a number of multichannel programs focused on precision medicine in oncology. Targeted Healthcare Communications is part of Michael J. Hennessy Associates Inc., a full-service healthcare communications company offering education, research, medical media and the acclaimed Targeted Oncology digital platform of resources on next-generation therapeutics and their molecular targets for practicing oncologists.
# # #
For the original version on PRWeb visit: http://www.prweb.com/releases/SITC/THC/prweb13402565.htm